Testosterone Testing
Customize your policy alerts
Sign up for Healthfirst Policy PO-RE-029v5 alerts
Get alerted when Policy PO-RE-029v5 changes without checking for updates manually.
Monitor payer policy activity
Clinical coverage criteria and scientific background for laboratory measurement of testosterone and related hormones, governing when testing is covered for Healthfirst members and clinical recommendations for providers.
No material clinical or coverage changes in this revision.
Coverage Criteria
Covered indications
Covered when the specified conditions below are met:
source: items 1.a-e
source: item 2
source: item 3
source: items 4 and 5
Not medically necessary / Not covered
Not covered in the following situations:
source: item 6
source: item 7
source: item 8
source: item 9
source: item 10
Guideline-based diagnostic and monitoring criteria
Guideline-based diagnostic and monitoring criteria (society statements):
Multiple societies recommend avoiding direct analog-based free testosterone immunoassays and favor LC-MS/MS when available.
Check hematocrit to monitor for polycythemia; assess PSA in men >40 prior to therapy.
Guidance summarized from Endocrine Society recommendations.
Recommendations referenced from ACOG, EAU, NCCN and others.
Use of saliva specimens for measurement of testosterone does not meet coverage criteria. The policy cites limited and inconsistent analytical validity data for salivary testosterone assays, including variability between immunoassay methods and findings that some immunoassays inflate low concentrations; although LC‑MS/MS methods for salivary steroids have been described, available studies do not provide sufficient, consistent evidence to support routine clinical use of saliva specimens for testosterone testing. Providers should therefore rely on validated serum assays for clinical decision making.
Direct analog‑based free testosterone immunoassays are discouraged by specialty guidance and are not recommended because of known inaccuracy. When free testosterone assessment is clinically indicated, societies endorse either a validated calculated free testosterone based on total testosterone, SHBG, and albumin or measurement by equilibrium dialysis (or other accepted direct methods), and they note that measurement of bioavailable testosterone using ammonium sulfate precipitation is technically challenging and not routinely recommended.
Revision history for the policy shows iterative literature reviews in 2023, 2024, and 2025. These reviews updated background material, guideline summaries, and references, but the documented literature reviews did not necessitate modifications to the coverage criteria during that period.
Measurement of serum free and/or bioavailable testosterone as a primary test without a prior total testosterone does not meet coverage criteria and may be denied. Similarly, testing of total, free, or bioavailable testosterone in asymptomatic individuals or those with non‑specific symptoms is designated as not meeting coverage criteria; these provisions reflect the requirement that total testosterone be the initial diagnostic test and that testing be tied to compatible clinical signs or symptoms.
Multiple professional societies recommend against routine universal screening of asymptomatic men for hypogonadism. The Endocrine Society explicitly recommends against routine screening of men in the general population, and the European Academy of Andrology similarly emphasizes obtaining morning total testosterone on two separate days and reserving further testing for men with compatible signs or symptoms.
Coding and Diagnostic Thresholds
| 82040 | Albumin; serum, plasma or whole blood. |
| 82642 | Dihydrotestosterone (DHT). |
| 82670 | Estradiol; total. |
| 82681 | Estradiol; free, direct measurement (eg, equilibrium dialysis). |
| 84270 | Sex hormone binding globulin (SHBG). |
| 84402 | Testosterone; free. |
| 84403 | Testosterone; total. |
| 84410 | Testosterone; bioavailable, direct measurement (eg, differential precipitation). |
Provider Actions, Authorization & Documentation
Prior authorization requirement
No explicit prior authorization rules are stated in this section; coverage is contingent on meeting the listed clinical criteria and the member's benefits at the time of the request.
Prior authorization guidance
The policy does not specify additional prior authorization guidance in this document segment.
Authorization and coding note
Procedure codes are provided as reference; reimbursement decisions depend on the member's evidence of coverage and may require adherence to payer authorization rules and coding/billing policies.
Step therapy
No step therapy requirements are specified in this part of the policy.
Step therapy (not specified)
Step therapy requirements are not specified in this document segment.
Required documentation elements
Document clinical signs or symptoms of androgen deficiency or excess, prior total testosterone results when available, and the timing of specimen collection (early morning, fasting) and assay method.
- Record presenting signs/symptoms of testosterone deficiency or excess.
- Include prior total testosterone results if performed.
- Document specimen timing as early morning and fasting, and note assay method (CDC HoSt-certified when available).
Required laboratory documentation
Record two fasting morning total testosterone results obtained on separate days and document associated clinical signs/symptoms; if total testosterone is borderline or SHBG-altering conditions exist, document rationale for measuring or calculating free testosterone.
- Two separate early-morning (fasting) total testosterone measurements on different days.
- Clinical signs/symptoms corresponding to the test results.
- Rationale for free-T measurement or calculated fT when TT is borderline or SHBG is altered.
Therapy monitoring documentation
For patients on testosterone therapy or androgen deprivation therapy, document baseline and follow-up total testosterone and hematocrit (and PSA in men >40 when initiating therapy), and record timing of sample relative to dosing.
- Baseline TT and hematocrit prior to therapy.
- Reassess at 3 and 6 months, then annually if stable.
- Document timing relative to injections (midway or pre-injection for long-acting IM) or transdermal dosing (≥1 week, ≥2 hours after application).
- For men >40, document PSA when initiating therapy.
Required clinical documentation
When clinically indicated (e.g., during systemic therapy follow-up), document castrate-level testosterone and obtain fasting morning (7–11 AM) samples; consider documenting related hormones such as PRL, SHBG, and LH when indicated.
- Document castrate serum testosterone level (<50 ng/dL) when indicated.
- Measure fasting morning TT in the 7–11 AM window for diagnosis.
- Document additional hormones (prolactin, SHBG, LH) as clinically indicated.
Primary test / Asymptomatic testing denial risk
Testing with serum free and/or bioavailable testosterone as a primary diagnostic test (without a prior total testosterone) or testing asymptomatic individuals does not meet coverage criteria and may be denied.
- Do not use free or bioavailable testosterone as the initial diagnostic test in place of total testosterone.
- Testing in asymptomatic persons or those with non-specific symptoms is not covered.
Requirement for repeat morning TT
Failure to obtain two separate early-morning total testosterone measurements before diagnosing testosterone deficiency may lead to inappropriate treatment decisions and denial of coverage.
- Diagnosis should be based on two TT measurements taken on separate occasions in the early morning.
Timing and repeat measurement
Not documenting two early-morning total testosterone samples or using non-morning/non-fasting samples could be noncompliant with guideline-based diagnostic processes and lead to coverage issues.
- AUA and others recommend two early-morning TT measurements on separate occasions.
- Ensure samples are collected in the early morning (fasting) to comply with guidance.
Coding and billing compliance risk
Failure to follow proper coding, billing, and reimbursement guidelines (including appropriate CPT use, modifiers, and payer rules) could result in claim denial or recoupment.
- Adhere to NCCI, NCD/LCD, CPT, HCPCS, and state-specific billing rules as applicable.
- Ensure coding aligns with documented clinical indication and policy criteria to avoid denial or recoupment.
Background and Rationale
Testosterone is an androgen produced primarily by the testes in males and by the ovaries and adrenal glands in females; it serves as a precursor for both dihydrotestosterone (DHT) and estradiol. Dysregulation of testosterone synthesis or action can lead to clinical syndromes of hypogonadism or androgen excess. Measurement considerations include the effects of sex hormone‑binding globulin (SHBG) on total versus free fractions, age‑related declines in total testosterone, and the need for early‑morning, fasting serum sampling to reduce biologic variability. Assessment of gonadotropins (LH, FSH) and other hormones (eg, prolactin) helps differentiate primary from secondary causes of hypogonadism, and accurate laboratory methods (eg, LC‑MS/MS and equilibrium dialysis for free hormone) are emphasized for reliable results.
Definitions
Revision History
Background, guidelines, recommendations, and evidence-based scientific references were updated following literature review; no changes to coverage criteria were required.
Background, guidelines, recommendations, and evidence-based scientific references were updated following literature review; no changes to coverage criteria were required.
Background, guidelines, recommendations, and evidence-based scientific references were updated following literature review; no changes to coverage criteria were required.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.